Fluicell ABOSTO:FLUI +2.32%54 PB Ratio is 2.99 as of Jul. 01, 2026, which is 10% below its 10-year median of 3.32. GuruFocus rates OSTO:FLUI with a GF Score™ of 54/100 and a GF Value™ of kr34.58 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,229 Biotechnology companies, Fluicell AB ranks worse than 50.37% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-01), Fluicell AB's share price is kr30.90. Fluicell AB's Book Value per Share for the quarter that ended in Mar. 2026 was kr10.34. Hence, Fluicell AB's PB Ratio of today is 2.99.
The historical rank and industry rank for Fluicell AB's PB Ratio or its related term are showing as below:
OSTO:FLUI'
s PB Ratio Range Over the Past 10 Years
Min: 0.72 Med: 3.32 Max: 162.34
Current: 2.99
During the past 11 years, Fluicell AB's highest PB Ratio was 162.34. The lowest was 0.72. And the median was 3.32.
OSTO:FLUI's PB Ratio is ranked worse than 50.37% of 1229
companies
in the Biotechnology industry
Industry Median: 2.87
vs OSTO:FLUI: 2.99
During the past 12 months, Fluicell AB's average Book Value Per Share Growth Rate was -14.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -53.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -49.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -14.80% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Fluicell AB was 200.50% per year. The lowest was -77.90% per year. And the median was -13.95% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Fluicell AB PB Ratio Related Terms
Fluicell AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Fluicell AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:FLUI vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Fluicell AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Fluicell AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Fluicell AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Fluicell AB (OSTO:FLUI) has a PB Ratio of 2.99 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fluicell AB and its competitors. This is 10% below median its historical median of 3.32. Over the past decade, Fluicell AB's PB Ratio has ranged from 0.72 to 162.34. According to the industry distribution chart, Fluicell AB ranks #619 out of 1229 companies in the Biotechnology industry, placing it in the top 50.4%.
Is Fluicell AB's PB Ratio too high?
Fluicell AB's current PB Ratio of 2.99 is 10% below median its 10-year median of 3.32. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 162.34. The Biotechnology industry median PB Ratio is 2.87. Fluicell AB's value of 2.99 is 4.2% above this industry median. Based on the distribution chart, Fluicell AB ranks #619 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Fluicell AB has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #619 out of 1229 companies for PB Ratio. This places Fluicell AB in the lower half of its industry. The industry median PB Ratio is 2.87. Fluicell AB's value of 2.99 is 4.2% above this benchmark. Historically, Fluicell AB's own PB Ratio has ranged from 0.72 to 162.34 over the past decade. While the company's 10-year median is 3.32 vs. the industry median of 2.87, Fluicell AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.87, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fluicell AB's current PB Ratio of 2.99 is 4.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fluicell AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fluicell AB's current PB Ratio is 2.99, which is 10% below median its own 10-year median of 3.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Modestly Undervalued. The stock's GF Value™ is kr34.58, compared to a current price of kr30.90 — trading 10.6% below its estimated fair value. The current PB Ratio is 2.99, which is 10% below median its 10-year median of 3.32 and 4.2% above the Biotechnology industry median of 2.87. Fluicell AB's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current PB Ratio is 2.99 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued.
The current stock price of kr30.90 is trading 10.6% below its estimated GF Value™ of kr34.58.
GuruFocus considers Fluicell AB to be Modestly Undervalued.
Key valuation signals for OSTO:FLUI:
PB Ratio: 2.99 (10% below median its 10-year median of 3.32)
GF Value™: kr34.58 vs. price of kr30.90 (10.6% below fair value)
Industry Position: 4.2% above the Biotechnology median (#619 of 1229)
No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
54GF Score
Get the complete analysis for OSTO:FLUI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:FLUI has been successfully added to your 
